Follicular lymphoma medical therapy

Follicular lymphoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Follicular lymphoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
Staging
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-Ray
CT scan
MRI
Echocardiography or Ultrasound
Biopsy
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Follicular lymphoma medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Follicular lymphoma medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Follicular lymphoma medical therapy
CDC on Follicular lymphoma medical therapy
Follicular lymphoma medical therapy in the news
Blogs on Follicular lymphoma medical therapy
Directions to Hospitals Treating Follicular lymphoma
Risk calculators and risk factors for Follicular lymphoma medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Medical Therapy

There is no consensus regarding the best treatment algorithm, but watch-and-wait policies, alkylators, anthracycline-containing regimens (eg. CHOP), rituximab, autologous and allogenic hematopoietic stem cell transplantation have all been applied. The exception is localized disease, which can be cured by local irradiation. The typical pattern is one of good responses from treatment, followed by relapses some years later. Median survival is around 10 years, but the range is wide, from less than one year, to more than 20 years. Some patients may never need treatment.